Swiss National Bank
CADX

Swiss National Bank’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Swiss National Bank’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-50,700
Closed -$459K – 2497
2013
Q4 		$459K Sell
50,700
-13,200
-21% -$95.3K ﹤0.01% 2036
2013
Q3 		$403K Sell
63,900
-6,200
-9% -$39.4K ﹤0.01% 2066
2013
Q2 		$478K Buy
+70,100
New +$488K ﹤0.01% 1953

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Swiss National Bank's CADX Position: Q1 2014 in Review

Swiss National Bank sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 50,700 shares — an estimated $459K sold.

Swiss National Bank first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $478K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Swiss National Bank reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Swiss National Bank sold 50,700 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $459K.
  • Swiss National Bank first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Swiss National Bank's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $478K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Swiss National Bank's 13F filing for Q1 2014, filed 6 May 2014.